# Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

> **NCT00021749** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genta Incorporated** · enrollment: 40 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- CLL

## Interventions

- **DRUG:** Oblimerson sodium, G3139

## Key facts

- **NCT ID:** NCT00021749
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2003-01
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021749, "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00021749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*